The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.
 
Anna-Maria Lazaratos
No Relationships to Disclose
 
Sarah M. Maritan
No Relationships to Disclose
 
Amelie Darlix
No Relationships to Disclose
 
Ivica Ratosa
No Relationships to Disclose
 
Emanuela Ferraro
No Relationships to Disclose
 
Gaia Griguolo
Consulting or Advisory Role - Gilead Sciences
Speakers' Bureau - Lilly; Novartis
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Novartis; Pfizer
 
Alessia Pellerino
No Relationships to Disclose
 
Silvia Hofer
No Relationships to Disclose
 
William Jacot
No Relationships to Disclose
 
Hans-Joachim Stemmler
No Relationships to Disclose
 
Marcel van den Broek
No Relationships to Disclose
 
Francois Panet
No Relationships to Disclose
 
Zubin Lahijanian
No Relationships to Disclose
 
Aki Morikawa
Consulting or Advisory Role - Eisai; Lilly; Seagen
Research Funding - Dantari Pharmaceuticals (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); F. Hoffmann LaRoche (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck Sharp & Dohme Corp. (Inst); Merrimack (Inst); Millenium Pharamceuticals (Inst); Molecular Templates (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Suzhou Zanrong Pharma (Inst); Tempus (Inst)
Other Relationship - Taiho Pharmaceutical
(OPTIONAL) Uncompensated Relationships - Puma Biotechnology
 
Andrew David Seidman
Honoraria - AstraZeneca; BeyondSpring Pharmaceuticals; Genentech/Roche; Genomic Health; Gilead Sciences; Lilly; Novartis; Pfizer
Consulting or Advisory Role - Affinia Therapeutics; BeyondSpring Pharmaceuticals; Cancer Expert Now; G1 Therapeutics; Genentech/Roche; Gilead/Forty Seven; Incyte; Lilly; Novartis; Pfizer
Speakers' Bureau - Genentech/Roche; Genentech/Roche; Genomic Health; Gilead Sciences; Lilly; Novartis/Pfizer
Research Funding - Bayer; Nektar (Inst); Odonate Therapeutics (Inst)
 
Riccardo Soffietti
No Relationships to Disclose
 
Kevin Petrecca
No Relationships to Disclose
 
April A. N. Rose
Employment - Merck (I)
Stock and Other Ownership Interests - Merck (I)
Consulting or Advisory Role - Pfizer
Research Funding - AstraZeneca Canada; Canadian Cancer Society; Canadian Institutes of Health Research (CIHR); Conquer Cancer Foundation; Jewish General Hospital Foundation; Merck; Pfizer; Seagen; TransMedTech Institute
 
Nathaniel Bouganim
No Relationships to Disclose
 
Matthew Dankner
No Relationships to Disclose